Phase II/III CRO Benchmarking – Small Pharma Market (4th Ed.)

Report Overview

Industry Standard Research understands the desire for a deeper dive regarding the small and emerging biopharma landscape. The needs, perceptions, and interactions of this segment are different compared to the wider audience of Phase II/III clinical development outsourcers.

The goal of this small and emerging biopharma report is two-fold: First, this research will help small and emerging biopharma companies make more informed CRO selection decisions. A trend we’ve seen over the years is that many smaller companies do not have preferred provider agreements. This report delves into the selection process and provides small and emerging biopharma companies metrics to make an educated decision for purchasing CRO services and the ability to narrow down which CROs might best fit their needs.

Second, these findings will help CROs optimize operational and marketing strategies to better accommodate small and emerging biopharma companies. The degree of detail provided in this report – straight from small and emerging biopharma customers – on CRO awareness, familiarity, reported use, and preference along with perceived leadership, cost perceptions, and CRO selection drivers will support your company’s marketing efforts to reach this segment, while communicating the information most valuable to them.

It is important to keep a pulse on this subset of companies as they continue to increase their role in drug development and innovation. ISR’s objectives remain the same – provide quality market research to ensure both sponsors and providers can glean what they need to make the best decisions possible for their clinical development programs and service offerings.

What you will learn:

Small & Emerging Sponsors:

• Gain insight into how your peers rate CROs, including verbatim reasons for satisfaction or dissatisfaction with Phase II/III services
• Learn which attributes are important among small and emerging sponsor companies with and without preferred provider agreements
• Discover how other small and emerging sponsors perceive the cost of Phase II/III service providers and their satisfaction with the value of services

Service Providers:

• Discover how your organization fares in perceived leadership, awareness, familiarity, and preference compared to competitors
• Determine which selection attributes are gaining importance to small and emerging sponsors
• Understand how small and emerging biopharma perceive the cost of your services compared to other Phase II/III providers, and view cost perceptions among recent users
   

Major Topics:

• Service Provider Selection Process
• Service Provider Perceptions and Interactions
• Study Data